PetVivo (PETV) 10-Q 27 Apr 18 2018 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Dec. 31, 2017	Apr. 26, 2018
Document And Entity Information
Entity Registrant Name	PetVivo Holdings, Inc.
Entity Central Index Key	1,512,922
Document Type	10-Q
Document Period End Date	Dec. 31, 2017
Amendment Flag	false
Current Fiscal Year End Date	--03-31
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		18,279,075
Trading Symbol	PETV
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2,018

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($)	Dec. 31, 2017	Mar. 31, 2017
Current Assets
Cash and cash equivalents	$ 556,901	$ 25,434
Accounts receivable	163	163
Employee advance	1,000
Prepaids	22,423	8,590
Security deposit	8,201
Total Current Assets	588,688	34,187
Property and Equipment:
Property & equipment	112,271	103,503
Less: accumulated depreciation	(103,470)	(103,054)
Total Fixed Assets	8,801	449
Other Assets:
Trademark and patents-net	1,399,043	1,862,301
Total Other Assets	1,399,043	1,862,301
Total Assets	1,996,532	1,896,937
Current Liabilities
Accounts payable & accrued expenses	1,278,807	643,890
Note payable and accrued interest-related party	196,063	197,055
Notes payable and line of credit loan	66,230	131,247
Convertible notes payable	115,736	105,000
Total Current Liabilities	1,656,836	1,077,192
Stockholders’ Equity:
Common stock, par value $0.001, 250,000,000 shares authorized, issued 18,279,075 and 9,321,306 shares outstanding at December 31, 2017 and March 31, 2017	18,279	9,322
Common stock to be issued	412,000	1,349,919
Additional Paid-In Capital	46,699,288	30,567,761
Accumulated Deficit	(46,789,871)	(45,410,816)
Total Stockholders’ Equity	339,696	(13,483,814)
Non-Controlling Interest		14,303,559
Total Stockholders’ Equity	339,696	819,745
Total Liabilities and Stockholders’ Equity	$ 1,996,532	$ 1,896,937

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares	Dec. 31, 2017	Mar. 31, 2017
Statement of Financial Position [Abstract]
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	250,000,000	250,000,000
Common stock, shares issued	18,279,075	9,321,306
Common stock, shares outstanding	18,279,075	9,321,306

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2017	Dec. 31, 2016
Income Statement [Abstract]
Revenues		$ 2,163	$ 1,510	$ 7,079
Cost of Sales
Gross Profit		2,163	1,510	7,079
Operating Expenses:
Research and Development	16,659	42,192	62,818	117,235
General and Administration	516,234	458,508	1,268,008	15,603,313
Total Operating Expenses	532,893	500,700	1,330,826	15,720,548
Operating Loss	(532,893)	(498,537)	(1,329,316)	(15,713,469)
Other Income (Expense)
Gain on Settlement of Debt	22,000		22,000	24,460
Interest Expense	(45,675)	(8,555)	(71,739)	(175,571)
Total Other Income (Expense)	(23,675)	(8,555)	(49,739)	(151,111)
Net Loss before taxes	(556,568)	(507,092)	(1,379,055)	(15,864,580)
Income Tax Provision
Net Loss	(556,568)	(507,092)	(1,379,055)	(15,864,580)
Net Loss Attributable To Non-Controlling Interest		225,092		772,794
Net loss attributable to PetVivo	$ (556,568)	$ (282,000)	$ (1,379,055)	$ (15,091,786)
Net Loss Per Share- Basic And Diluted	$ (0.03)	$ (0.03)	$ (0.08)	$ (1.68)
Weighted Average Common Shares Outstanding-Basic And Diluted	17,168,329	9,081,482	16,506,923	9,000,488

Condensed Consolidated Stateme5

Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) - USD ($)	Common Stock [Member]	Additional Paid-In Capital [Member]	Accumulated Deficit [Member]	Non-controlling Interest [Member]	Stock to be Issued [Member]	Total
Balance at Mar. 31, 2016	$ 7,931	$ 28,224,376	$ (29,879,283)	$ 15,280,865	$ 1,576,649	$ 15,210,538
Balance, shares at Mar. 31, 2016	7,931,639
Common stock to be issued					1,349,919	1,349,919
Common shares issued to settle debt	$ 789	1,575,860			(1,576,649)
Common shares issued to settle debt, shares	788,325
Common stock issued for cash	$ 67	99,684				99,751
Common stock issued for cash, shares	66,500
Common stock issued for services	$ 438	382,062				382,500
Common stock issued for services, shares	437,500
Common shares issued for interest	$ 97	151,379				151,476
Common shares issued for interest, shares	97,342
Common stock issued for services-Gel-Del				12,859		12,859
Warrants issued for services		134,400				134,400
Net loss			(15,531,533)	(990,165)		(16,521,698)
Balance at Mar. 31, 2017	$ 9,322	30,567,761	(45,410,816)	14,303,559	1,349,919	819,745
Balance, shares at Mar. 31, 2017	9,321,306
Common stock issued for cash	$ 1,620	565,380			(567,000)
Common stock issued for cash, shares	1,620,000
Common stock issued for services	$ 431	214,394			(214,825)
Common stock issued for services, shares	431,500
Common shares issued for interest
Common stock issued for services-Gel-Del				32,171		32,171
Common stock issued to reduce accrued salaries	$ 2,100	1,207,819			(1,209,919)
Common stock issued to reduce accrued salaries, shares	2,100,128
Common stock issued to reduce debt	$ 38	13,172			(13,210)
Common stock issued to reduce debt, shares	37,741					37,741
Proceeds from stock sale					877,000	877,000
Common stock returned	$ (682)	(342,045)				(342,727)
Common stock returned, shares	(681,600)
Stock based compensation granted		112,527			176,825	289,352
Stock granted for debt conversion					13,210	13,210
Inducement dividend		30,000				30,000
Change in ownership in VIE	$ 5,450	14,330,280		(14,335,730)
Change in ownership in VIE, shares	5,450,000
Net loss			(1,379,055)			(1,379,055)
Balance at Dec. 31, 2017	$ 18,279	$ 46,699,288	$ (46,789,871)		$ 412,000	$ 339,696
Balance, shares at Dec. 31, 2017	18,279,075

Condensed Consolidated Stateme6

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2017	Dec. 31, 2016	Mar. 31, 2017
CASH FLOWS FROM OPERATING ACTIVITIES:
Net Loss For The Period	$ (556,568)	$ (507,092)	$ (1,379,055)	$ (15,864,580)	$ (16,521,698)
Adjustments to Reconcile Net Loss to Net Cash Used in Operating Activities:
Induced dividend from warrant exercise			30,000
Gain on debt settlement	(22,000)		(22,000)	(24,460)
Non cash consulting expense				134,400
Stock based compensation			321,523	232,500
Stock compensation adjustment			(342,727)
Stock issued for interest				151,476	(151,476)
Depreciation and amortization			483,317	583,966
Goodwill and patent impairment loss				14,081,031
Forgiveness of debt				(24,460)
Changes in Operating Assets and Liabilities
Increase (decrease) in prepaid expense			(13,833)	5,390
Increase (decrease) in advances and receivables			(1,000)	15,900
Increase in accounts payable and accrued expense			677,924	596,423
Net Cash Used In Operating Activities			(245,851)	(87,954)
CASH FLOWS FROM INVESTING ACTIVITIES
Decrease in security deposit			(8,201)
Purchase of equipment			(8,768)
Change in intangible assets			(19,643)	(31,833)
Net Cash Used in Investing Activities			(36,612)	(31,833)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from stock sale			877,000	99,750
Stock issued to convert debt			13,210
Decrease in notes to related parties			(2,168)	4,305
Proceeds from loan				12,500
Debt conversion			(12,500)
Common stock subscribed				60,200
Repayments of convertible notes				(35,000)
Repayments of loans and line of credit			(61,612)	(19,137)
Net Cash Provided by Financing Activities			813,930	122,618
Net Increase in Cash			531,467	2,831
Cash at Beginning of Period			25,434	258	258
Cash at End of Period	$ 556,901	$ 3,089	556,901	3,089	$ 25,434
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Cash Paid During The Year For: Interest
Cash Paid During The Year For: Income taxes paid
SUPPLEMENTAL DISCLOSURE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:
Shares issued as payment for accrued salaries			1,209,919
Change in variable interest equity			$ 14,335,730

Summary of Significant Accounti

Summary of Significant Accounting Policies and Organization	9 Months Ended
	Dec. 31, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Summary of Significant Accounting Policies and Organization	NOTE 1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ORGANIZATION (A) Basis of Presentation PetVivo Holdings, Inc. (the “Company”) was incorporated in Nevada under a former name in 2009, and entered its current business in 2014 through a stock exchange reverse merger with PetVivo, Inc., a Minnesota corporation. This merger resulted in Minnesota PetVivo becoming a wholly-owned subsidiary of the Company. In April 2017, the Company acquired another Minnesota corporation, Gel-Del Technologies, Inc., through a statutory merger, which is also a wholly owned subsidiary of the Company. The accompanying condensed consolidated financial statements are unaudited. These unaudited interim financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) and pursuant to the rules and regulations of the SEC. Certain information and note disclosures, which are included in annual financial statements, have been omitted pursuant to these rules and regulations. We believe the disclosures made in these interim unaudited financial statements are adequate to make the information not misleading. Although these interim financial statements at December 31, 2017 and for the nine months ended December 31, 2017 and 2016 are unaudited, in the opinion of our management, such statements include all adjustments (consisting of normal recurring entries) necessary to present fairly our financial position, results of operations and cash flows for the periods presented. The results for the nine months ended December 31, 2017 are not necessarily indicative of the results to be expected for the year ended March 31, 2018 or for any future period. These unaudited interim financial statements should be read and considered in conjunction with our audited financial statements and the notes thereto for the year ended March 31, 2017, included in our annual report on Form 10-K filed with the SEC. The Company is in the business of distribution of medical devices and biomaterials for the treatment of afflictions and diseases in animals. The Company’s management development and other operations are conducted from its headquarter facilities in suburban Minneapolis, Minnesota. (B) Principles of Consolidation The accompanying condensed consolidated financial statements include the accounts of the Company and its two wholly-owned Minnesota corporations. All intercompany accounts have been eliminated upon consolidation. The accounting for the acquisition of Gel-Del Technologies, Inc. began with the Security Exchange Agreement on April 10, 2015 which was uncompleted and abandoned in 2016, and as adjusted for completion pursuant to the Agreement and Plan of Merger effective April 10, 2017 (the “Merger”). To complete the Merger, the Company issued 5,450,000 shares valued at market at $0.40 per share, which equaled $2,180,000. (C) Use of Estimates In preparing financial statements in conformity with generally accepted accounting principles, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and revenues and expenses during the reported period. Actual results could differ from those estimates. Significant estimates include estimated useful lives and potential impairment of property and equipment, estimate of fair value of share based payments and derivative instruments and recorded debt discount, valuation of deferred tax assets and valuation of in-kind contribution of services and interest. (D) Cash and Cash Equivalents The Company considers all highly liquid temporary cash investments with an original maturity of three months or less to be cash equivalents. At December 31, 2017 and March 31, 2018, the Company had no cash equivalents. (E) Concentration-Risk The Company maintains its cash with various financial institutions, which at times may exceed federally insured limits. (F) Machinery & Equipment Machinery and equipment are recorded at cost. Expenditures for major additions and betterments are capitalized. Maintenance and repairs are charged to operations as incurred. Depreciation of furniture fixtures and equipment is computed by the straight-line method (after taking into account their respective estimated residual values) over the assets estimated useful life of five (3) years for equipment, (5) years for automobile, and (7) years for furniture and fixtures. (G) Patents and Trademarks The company capitalizes direct costs for the maintenance and advancement of their patents and trademarks and amortizes these costs over a useful life of 60 months. (H) Loss Per Share Basic loss per share is computed by dividing net loss by weighted average number of shares of common stock outstanding during each period. Diluted loss per share is computed by dividing net loss by the weighted average number of shares of common stock, common stock equivalents and potentially dilutive securities outstanding during the period. The Company has 2,646,036 warrants outstanding as of December 31, 2017 with varying exercise prices ranging from $3.50 to $0.30/share. The weighted average exercise price for these warrants is $ 0.52 per share. These warrants are antidilutive and have been excluded from the weighted average number of shares. (I) Revenue Recognition The Company will recognize revenue on arrangements in accordance with FASB ASC No. 605, “Revenue Recognition”. In all cases, revenue is recognized only when the price is fixed and determinable, persuasive evidence of an arrangement exists, the service is performed and collectability of the resulting receivable is reasonably assured. Revenues consist of Kush product sales to veterinary clinics. (J) Research and Development The Company expenses research and development costs as incurred. (K) Fair Value of Financial Instruments The Company applies the accounting guidance under Financial Accounting Standards Board (“FASB”) ASC 820-10, “Fair Value Measurements”, The guidance also establishes a fair value hierarchy for measurements of fair value as follows: ● Level 1 - quoted market prices in active markets for identical assets or liabilities. ● Level 2 - inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. ● Level 3 - unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. The Company’s financial instruments consist of accounts receivable, accounts payable, accrued expenses, notes payable, notes payable - related party, and convertible notes payable. The carrying amount of the Company’s financial instruments approximates their fair value as of December 31, 2017 and March 31, 2017, due to the short-term nature of these instruments. In instances where the determination of the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment, and considers factors specific to the asset or liability. The valuation of the Company’s notes recorded at fair value is determined using Level 3 inputs, which consider (i) time value, (ii) current market and (iii) contractual prices. The Company had no assets and liabilities measured at fair value on a recurring basis at December 31, 2017 and March 31, 2017. (L)Recent Accounting Pronouncements The FASB issued ASC 606 as guidance on the recognition of revenue from contracts with customers in May 2014 with amendments in 2015 and 2016. Revenue recognition will depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The guidance also requires disclosures regarding the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers. The guidance permits two methods of adoption: retrospectively to each prior reporting period presented, or retrospectively with the cumulative effect of initially applying the guidance recognized at the date of initial application (the cumulative catch-up transition method). The company will adopt the guidance on April 1, 2018 and apply the cumulative catchup transition method. The transition adjustment to be recorded to stockholders’ equity upon adoption of the new standard is not expected to be material. The Company does not expect the adoption on this new standard to have any material effect upon the financial statements. In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. Topic 842 affects any entity that enters into a lease, with some specified scope exemptions. The guidance in this ASU supersedes Topic 840, Leases. The core principle of Topic 842 is that a lessee should recognize the assets and liabilities that arise from leases. A lessee should recognize in the statement of financial position a liability to make lease payments (the lease liability) and a right-of-use (“ROU”) asset representing its right to use the underlying asset for the lease term. For public companies, the amendments in this ASU are effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. The Company expects to recognize ROU assets and related obligations upon adoption of ASU 2016-02. The Company does not expect the adoption on this new standard to have any material effect upon the financial statements. All other newly issued accounting pronouncements but not yet effective have been deemed either immaterial or not applicable.

Convertible Notes Payable

Convertible Notes Payable	9 Months Ended
	Dec. 31, 2017
Debt Disclosure [Abstract]
Convertible Notes Payable	NOTE 2 - CONVERTIBLE NOTES PAYABLE The Company has one convertible note outstanding as of December 31, 2017 in the amount of $105,000 plus accrued interest of $10,736. The note terms include: twelve percent annual interest rate with the stipulation including upon completion of the Company’s next qualified equity financing round the note holder shall be allowed to exchange this note pursuant to the same terms and conditions offered in the qualified offering.

Related Party Payable

Related Party Payable	9 Months Ended
	Dec. 31, 2017
Related Party Transactions [Abstract]
Related Party Payable	NOTE 3 - RELATED PARTY PAYABLE At December 31, 2017, the company is obligated for officers’ notes payable, accounts payable and accrued interest in the total amount of $196,063. The note payable to officer terms are accrual of interest at eight percent annually, with a stipulation including if the Company receives additional financing in the amount greater than $1,400,000, the Company will immediately pay the officer the principal amount of the note along with all interest due.

Note Payable

Note Payable	9 Months Ended
	Dec. 31, 2017
Debt Disclosure [Abstract]
Note Payable	NOTE 4 - NOTE PAYABLE The Company is obligated on the following notes at December 31, 2017: 1. Third Party Individuals $ 181,966 2. Bank Credit Line 18,333 Total $ 200,299

Going Concern

Going Concern	9 Months Ended
	Dec. 31, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Going Concern	NOTE 5 - GOING CONCERN As reflected in the accompanying condensed consolidated financial statements, the Company had no significant revenue and had a negative equity and recurring material losses. These factors raise substantial doubt about the Company’s ability to continue as a going concern. Management intends to raise additional funds either through a private placement or public offering of its equity securities. Management believes that the actions presently being taken to further implement its business plan will enable the Company to continue as a going concern. While the Company believes in its viability to raise additional funds, there can be no assurances to that effect. The ability of the Company to continue as a going concern is dependent upon the Company’s ability to further implement its business plan and raise additional funds. These financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.

Common Stock

Common Stock	9 Months Ended
	Dec. 31, 2017
Equity [Abstract]
Common Stock	NOTE 6 - COMMON STOCK From April 1, 2017 to December 31, 2017, the Company issued 8,957,769 shares of common stock of which 1,418,528 were issued to reduce accrued salaries valued at $867,192; 431,500 shares were for services valued at market for $214,825; and 1,620,000 shares for cash of $567,000. In addition, 5,450,000 shares were issued as part of the Company’s merger of Gel-Del Technologies, Inc. In December, 2017, 37,741 shares were issued to settle debt valued at $13,210. As of December 31, 2017, the Company had 2,646,036 warrants outstanding. On August 5, 2015, 40,000 warrants were issued as settlement for business advising, management consulting, fund raising and public relations consulting at exercise price of $3.50/share for a five year term. On April 11, 2016, 20,000 warrants were issued as part of subscription agreements at an exercise price of $2.00/share for a term of five years. On June 7, 2016, 13,250 warrants were issued as part of a subscription agreement at an exercise price of $2.00/share for a term of five years. On September 15, 2017, the Company issued 100,000 warrants to David Deming and 100,000 warrants to Peter Vezmar at an exercise price of $0.35/share for a five year term. On September 19, 2016, 60,000 warrants were issued as part of a subscription agreement at an exercise price of $1.50/share for a term of five years. On July 28, 2017, 750,000 warrants were issued to the President upon the transfer of his 1.25 million shares to the new CEO at an exercise price of $0.30/share for a vesting term of two years. On November 6, 2017, the Company issued 100,000 warrants to David Merrill as a board member at an exercise price of $1.00/share for a five year term. On December 7, 2017, the Company issued 1,500,000 warrants as part of subscription agreements at an exercise price of $0.50/share for a three year term. On December 18, 2017, the Company issue 22,786 warrants as part of a conversion of a note payable at an exercise price of $0.50/share for a three year term. On December 28, 2017, one warrant holder exercised 60,000 warrants at $1.00/share.

Agreement and Plan of Merger

Agreement and Plan of Merger	9 Months Ended
	Dec. 31, 2017
Agreement And Plan Of Merger - Schedule Of Recognized Identified Assets Acquired And Liabilities Assumed Details
Agreement and Plan of Merger	NOTE 7 - AGREEMENT AND PLAN OF MERGER In November 2014early 2015, we entered into a business combination agreement with Gel-Del Technologies, Inc, a Minnesota corporation (“Gel-Del”) and incident thereto in early 2015 shareholder approval of this agreement was obtained from both our shareholders and Gel-Del shareholders. We then concluded for this pending merger that Gel-Del was a VIE entity for which we were the primary beneficiary. Accordingly, for future accounting purposes, we consolidated our financial statements with those of Gel-Del as our VIE entity. We also valued Gel-Del in this uncompleted merger based on the trading price of our common stock in early 2015. In late 2016 we abandoned the uncompleted 2015 business combination since Gel-Del management no longer agreed to complete it due to a substantial decline in the value of our common stock as well as a perceived higher value of Gel-Del based on additional patents granted for Gel-Del technology. During early 2017, our management and Gel-Del management again entered into a definitive agreement to effect a merger to replace the abandoned merger, provided we issue an additional 31.3% of our common stock to Gel-Del shareholders than was required by our abandoned merger. This 2017 merger agreement was then concluded through a statutory triangular merger, whereby Gel-Del and a wholly-owned Minnesota subsidiary of ours (formed expressly for the purpose of this transaction) completed a statutory merger under Minnesota Statutes (the “Merger”). Pursuant to the Merger, Gel-Del was the surviving entity and concurrently became our wholly-owned subsidiary, resulting in our obtaining full ownership of Gel-Del. Our primary reason to effect the Merger was to obtain 100% ownership and control of Gel-Del and its patented bioscience technology, including ownership of Gel-Del’s Cosmeta subsidiary. The effective and acquisition date for the Merger was April 10, 2017 when the Merger was filed officially with the Secretary of State of Minnesota. As a result of the Merger we issued a total of 5,450,000 shares of our common stock pro rata to the pre-merger shareholders of Gel-Del, resulting in each common share of Gel-Del outstanding immediately prior to the Merger effective date being converted into the right to receive 0.788 common shares of our company. Gel-Del did not have any outstanding options, warrants, other derivative securities or rights convertible into securities. Incident to the Merger, we also recorded an impairment loss of $14,335,730 related to an adjustment of our earlier valuation of Gel-Del which had been used in the abandoned 2015 business combination. Total consideration for this Gel-Del merger was comprised of 5,450,000 shares of our common stock with an estimated fair value of $2,180,000, which 5,450,000 shares then represented approximately 30% of our total post-merger outstanding common stock. The Merger was accounted for using the acquisition method of accounting and the purchase price was allocated to the net assets acquired at their estimated fair value as follows: Current assets $ 13,918 Property and equipment 107,300 Intangible assets (patents & trademarks) 2,180,000 Non-controlling interest in Gel-Del 1,422,180 Total assets acquired 3,723,398 Total liabilities assumed 1,543,398 Net assets acquired $ 2,180,000 The allocation of $1,422,180 for the controlling interest in Gel-Del was completely eliminated or impaired after the Merger became effective in order to remove it from future consolidated interim and annual financial statements.

Income Taxes

Income Taxes	9 Months Ended
	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Income Taxes	NOTE 8 – INCOME TAXES The Company has not filed tax returns for 2014, 2015, 2016, and 2017. The Company’s subsidiaries, Gel-Del Technologies, Inc., and Cosmeta Corp have not filed tax returns for tax years 2013, 2014, 2015, 2016, and 2017. It should be noted that the tax liability for all the companies for those years is likely to be none or minimal as a result of net operating losses recorded in those years. Gel-Del Technologies, Inc. and Cosmeta Corp file consolidated returns. There are penalties for not filing timely returns. These penalties have not been determined at this time, however, due to the operating losses, penalties are expected to be minimal. The Company is now in the process of filing all untimely returns, which will soon be submitted as required.

Lease and Commitments

Lease and Commitments	9 Months Ended
	Dec. 31, 2017
Commitments and Contingencies Disclosure [Abstract]
Lease and Commitments	NOTE 9 – LEASE AND COMMITMENTS The Company entered into an eighty-four month lease for 3,577 square feet of newly constructed office, laboratory and warehouse space located in Edina, Minnesota on May 3, 2017. The base rent is $2,078 per month and the Company is responsible for its proportional share of common space expenses, property taxes, and building insurance. Future minimum rental commitments are as follows: 2018 $ 24,932 2019 24,932 2020 24,932 2021 24,932 2022 24,932 2023 24,932 2024 21,774 $ 171,366

Subsequent Events

Subsequent Events	9 Months Ended
	Dec. 31, 2017
Subsequent Events [Abstract]
Subsequent Events	NOTE 10 – SUBSEQUENT EVENTS On February 2018, the Company converted note payables in the amount of $181,966 into 425,287 shares of common stock and 330,673 purchase warrants with an exercise price of $0.50 per share with a three year term. In February 2018, the Company granted 10,000 shares valued at $1.50 per share for consulting and business management services. In February 2018, the Company engaged a new patent law firm and granted 20,000 purchase warrants with an exercise price of $1.00 per share with a three year term. All of the foregoing securities issuances were unregistered and made as non-public transactions, and accordingly exempt from registration in reliance on Section 4(a)(2) of the Securities Act of 1933, as amended.

Summary of Significant Accoun17

Summary of Significant Accounting Policies and Organization (Policies)	9 Months Ended
	Dec. 31, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	A) Basis of Presentation PetVivo Holdings, Inc. (the “Company”) was incorporated in Nevada under a former name in 2009, and entered its current business in 2014 through a stock exchange reverse merger with PetVivo, Inc., a Minnesota corporation. This merger resulted in Minnesota PetVivo becoming a wholly-owned subsidiary of the Company. In April 2017, the Company acquired another Minnesota corporation, Gel-Del Technologies, Inc., through a statutory merger, which is also a wholly owned subsidiary of the Company. The accompanying condensed consolidated financial statements are unaudited. These unaudited interim financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) and pursuant to the rules and regulations of the SEC. Certain information and note disclosures, which are included in annual financial statements, have been omitted pursuant to these rules and regulations. We believe the disclosures made in these interim unaudited financial statements are adequate to make the information not misleading. Although these interim financial statements at December 31, 2017 and for the nine months ended December 31, 2017 and 2016 are unaudited, in the opinion of our management, such statements include all adjustments (consisting of normal recurring entries) necessary to present fairly our financial position, results of operations and cash flows for the periods presented. The results for the nine months ended December 31, 2017 are not necessarily indicative of the results to be expected for the year ended March 31, 2018 or for any future period. These unaudited interim financial statements should be read and considered in conjunction with our audited financial statements and the notes thereto for the year ended March 31, 2017, included in our annual report on Form 10-K filed with the SEC. The Company is in the business of distribution of medical devices and biomaterials for the treatment of afflictions and diseases in animals. The Company’s management development and other operations are conducted from its headquarter facilities in suburban Minneapolis, Minnesota.
Principles of Consolidation	(B) Principles of Consolidation The accompanying condensed consolidated financial statements include the accounts of the Company and its two wholly-owned Minnesota corporations. All intercompany accounts have been eliminated upon consolidation. The accounting for the acquisition of Gel-Del Technologies, Inc. began with the Security Exchange Agreement on April 10, 2015 which was uncompleted and abandoned in 2016, and as adjusted for completion pursuant to the Agreement and Plan of Merger effective April 10, 2017 (the “Merger”). To complete the Merger, the Company issued 5,450,000 shares valued at market at $0.40 per share, which equaled $2,180,000.
Use of Estimates	(C) Use of Estimates In preparing financial statements in conformity with generally accepted accounting principles, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and revenues and expenses during the reported period. Actual results could differ from those estimates. Significant estimates include estimated useful lives and potential impairment of property and equipment, estimate of fair value of share based payments and derivative instruments and recorded debt discount, valuation of deferred tax assets and valuation of in-kind contribution of services and interest.
Cash and Cash Equivalents	(D) Cash and Cash Equivalents The Company considers all highly liquid temporary cash investments with an original maturity of three months or less to be cash equivalents. At December 31, 2017 and March 31, 2018, the Company had no cash equivalents.
Concentration-Risk	(E) Concentration-Risk The Company maintains its cash with various financial institutions, which at times may exceed federally insured limits.
Machinery & Equipment	(F) Machinery & Equipment Machinery and equipment are recorded at cost. Expenditures for major additions and betterments are capitalized. Maintenance and repairs are charged to operations as incurred. Depreciation of furniture fixtures and equipment is computed by the straight-line method (after taking into account their respective estimated residual values) over the assets estimated useful life of five (3) years for equipment, (5) years for automobile, and (7) years for furniture and fixtures.
Patents and Trademarks	(G) Patents and Trademarks The company capitalizes direct costs for the maintenance and advancement of their patents and trademarks and amortizes these costs over a useful life of 60 months.
Loss Per Share	(H) Loss Per Share Basic loss per share is computed by dividing net loss by weighted average number of shares of common stock outstanding during each period. Diluted loss per share is computed by dividing net loss by the weighted average number of shares of common stock, common stock equivalents and potentially dilutive securities outstanding during the period. The Company has 2,646,036 warrants outstanding as of December 31, 2017 with varying exercise prices ranging from $3.50 to $0.30/share. The weighted average exercise price for these warrants is $ 0.52 per share. These warrants are antidilutive and have been excluded from the weighted average number of shares.
Revenue Recognition	(I) Revenue Recognition The Company will recognize revenue on arrangements in accordance with FASB ASC No. 605, “Revenue Recognition”. In all cases, revenue is recognized only when the price is fixed and determinable, persuasive evidence of an arrangement exists, the service is performed and collectability of the resulting receivable is reasonably assured. Revenues consist of Kush product sales to veterinary clinics.
Research and Development	(J) Research and Development The Company expenses research and development costs as incurred.
Fair Value of Financial Instruments	(K) Fair Value of Financial Instruments The Company applies the accounting guidance under Financial Accounting Standards Board (“FASB”) ASC 820-10, “Fair Value Measurements”, The guidance also establishes a fair value hierarchy for measurements of fair value as follows: ● Level 1 - quoted market prices in active markets for identical assets or liabilities. ● Level 2 - inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. ● Level 3 - unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. The Company’s financial instruments consist of accounts receivable, accounts payable, accrued expenses, notes payable, notes payable - related party, and convertible notes payable. The carrying amount of the Company’s financial instruments approximates their fair value as of December 31, 2017 and March 31, 2017, due to the short-term nature of these instruments. In instances where the determination of the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment, and considers factors specific to the asset or liability. The valuation of the Company’s notes recorded at fair value is determined using Level 3 inputs, which consider (i) time value, (ii) current market and (iii) contractual prices. The Company had no assets and liabilities measured at fair value on a recurring basis at December 31, 2017 and March 31, 2017.
Recent Accounting Pronouncements	(L)Recent Accounting Pronouncements The FASB issued ASC 606 as guidance on the recognition of revenue from contracts with customers in May 2014 with amendments in 2015 and 2016. Revenue recognition will depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The guidance also requires disclosures regarding the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers. The guidance permits two methods of adoption: retrospectively to each prior reporting period presented, or retrospectively with the cumulative effect of initially applying the guidance recognized at the date of initial application (the cumulative catch-up transition method). The company will adopt the guidance on April 1, 2018 and apply the cumulative catchup transition method. The transition adjustment to be recorded to stockholders’ equity upon adoption of the new standard is not expected to be material. The Company does not expect the adoption on this new standard to have any material effect upon the financial statements. In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. Topic 842 affects any entity that enters into a lease, with some specified scope exemptions. The guidance in this ASU supersedes Topic 840, Leases. The core principle of Topic 842 is that a lessee should recognize the assets and liabilities that arise from leases. A lessee should recognize in the statement of financial position a liability to make lease payments (the lease liability) and a right-of-use (“ROU”) asset representing its right to use the underlying asset for the lease term. For public companies, the amendments in this ASU are effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. The Company expects to recognize ROU assets and related obligations upon adoption of ASU 2016-02. The Company does not expect the adoption on this new standard to have any material effect upon the financial statements. All other newly issued accounting pronouncements but not yet effective have been deemed either immaterial or not applicable.

Note Payable (Tables)

Note Payable (Tables)	9 Months Ended
	Dec. 31, 2017
Debt Disclosure [Abstract]
Summary of Note Payable	The Company is obligated on the following notes at December 31, 2017: 1. Third Party Individuals $ 181,966 2. Bank Credit Line 18,333 Total $ 200,299

Agreement and Plan of Merger (T

Agreement and Plan of Merger (Tables)	12 Months Ended
	Dec. 31, 2017
Agreement And Plan Of Merger - Schedule Of Recognized Identified Assets Acquired And Liabilities Assumed Details
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed	The Merger was accounted for using the acquisition method of accounting and the purchase price was allocated to the net assets acquired at their estimated fair value as follows: Current assets $ 13,918 Property and equipment 107,300 Intangible assets (patents & trademarks) 2,180,000 Non-controlling interest in Gel-Del 1,422,180 Total assets acquired 3,723,398 Total liabilities assumed 1,543,398 Net assets acquired $ 2,180,000

Lease and Commitments (Tables)

Lease and Commitments (Tables)	9 Months Ended
	Dec. 31, 2017
Commitments and Contingencies Disclosure [Abstract]
Schedule of Future Minimum Rental Commitments	Future minimum rental commitments are as follows: 2018 $ 24,932 2019 24,932 2020 24,932 2021 24,932 2022 24,932 2023 24,932 2024 21,774 $ 171,366

Summary of Significant Accoun21

Summary of Significant Accounting Policies and Organization (Details Narrative) - USD ($)	Apr. 10, 2017	Dec. 31, 2017	Dec. 28, 2017	Dec. 18, 2017	Jul. 28, 2017	Sep. 19, 2016	Jun. 07, 2016	Apr. 11, 2016	Aug. 05, 2015
Cash equivalents
Estimated useful life of assets		5 years
Warrants outstanding		2,646,036	60,000	22,786		60,000	13,250	20,000	40,000
Weighted average exercise price of warrants price per share		$ 0.52	$ 1	$ 0.50	$ 0.30	$ 1.50	$ 2	$ 2	$ 3.50
Minimum [Member]
Weighted average exercise price of warrants price per share		0.30
Maximum [Member]
Weighted average exercise price of warrants price per share		$ 3.50
Patents And Trademarks [Member]
Estimated useful life of assets		60 months
Equipment [Member]
Estimated useful life of assets		3 years
Automobiles [Member]
Estimated useful life of assets		5 years
Furniture and Fixtures [Member]
Estimated useful life of assets		7 years
March 31, 2018 [Member]
Cash equivalents
Gel-Del Technologies, Inc [Member]
Number of shares issued during period	5,450,000
Market price per share	$ 0.40
Issued shares equaled value	$ 2,180,000

Convertible Notes Payable (Deta

Convertible Notes Payable (Details Narrative)	Dec. 31, 2017USD ($)
Debt instrument, interest rate, percentage	8.00%
Convertible Notes Payable [Member]
Convertible note face amount	$ 105,000
Accrued interest	$ 10,736
Debt instrument, interest rate, percentage	12.00%

Related Party Payable (Details

Related Party Payable (Details Narrative) - USD ($)	Dec. 31, 2017	Mar. 31, 2017
Note payable and accrued interest	$ 196,063	$ 197,055
Debt instrument, interest rate, percentage	8.00%
Minimum [Member]
Additional financing	$ 1,400,000

Note Payable - Summary of Note

Note Payable - Summary of Note Payable (Details)	Dec. 31, 2017USD ($)
Debt Disclosure [Abstract]
Third Party Individuals	$ 181,966
Bank Credit Line	18,333
Total	$ 200,299

Common Stock (Details Narrative

Common Stock (Details Narrative) - USD ($)	Dec. 18, 2017	Dec. 07, 2017	Nov. 06, 2017	Sep. 15, 2017	Jul. 28, 2017	Sep. 19, 2016	Jun. 07, 2016	Apr. 11, 2016	Aug. 05, 2015	Dec. 31, 2017	Dec. 31, 2017	Mar. 31, 2017	Dec. 28, 2017
Number of shares issued during period for services
Number of shares issued during period for services, value												$ (382,500)
Number of shares issued during period, shares											5,450,000
Number of shares issued during period											$ (2,180,000)	$ (99,751)
Common stock issued to reduce debt
Common stock issued to reduce debt, shares										$ 37,741
Warrants outstanding	22,786					60,000	13,250	20,000	40,000	2,646,036	2,646,036		60,000
Exercise price per share of warrants	$ 0.50				$ 0.30	$ 1.50	$ 2	$ 2	$ 3.50	$ 0.52	$ 0.52		$ 1
Warrant term	3 years			5 years	2 years	5 years	5 years	5 years	5 years
Subscription Agreement [Member]
Warrants outstanding		1,500,000
Exercise price per share of warrants		$ 0.50
Warrant term		3 years
David Deming [Member]
Warrants outstanding				100,000
Peter Vezmar [Member]
Warrants outstanding				100,000
Exercise price per share of warrants				$ 0.35
President [Member]
Warrants outstanding					750,000
Chief Executive Officer [Member]
Warrants outstanding					1,250,000
David Merrill [Member]
Warrants outstanding			100,000
Exercise price per share of warrants			$ 1
Warrant term			5 years
Common Stock [Member]
Number of shares issued, shares										8,957,769
Number of common stock issued to reduce accrued salaries, shares										1,418,528
Number of common stock issued to reduce accrued salaries										$ 867,192
Number of shares issued during period for services										431,500		437,500
Number of shares issued during period for services, value										$ (431)		$ (438)
Number of shares issued during period, shares										1,620,000		66,500
Number of shares issued during period										$ (1,620)		$ (67)
Stock Issued During Period, Shares, Acquisitions										5,450,000
Common stock issued to reduce debt										$ 38
Common stock issued to reduce debt, shares										37,741
Stock to be Issued [Member]
Number of shares issued during period for services, value										214,825
Number of shares issued during period										567,000
Common stock issued to reduce debt										$ (13,210)

Agreement and Plan of Merger (D

Agreement and Plan of Merger (Details Narrative) - USD ($)	9 Months Ended	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2017	Mar. 31, 2017
Agreement And Plan Of Merger - Schedule Of Recognized Identified Assets Acquired And Liabilities Assumed Details
Ownership percentage	100.00%	100.00%
Number of common stock shares issued		5,450,000
Number of common stock value issued		$ 2,180,000	$ 99,751
Merger agreement converted, description		Merger effective date being converted into the right to receive 0.788 common shares of our company.
Impairment loss		$ 14,335,730
Acquisition of common stock outstanding, percentage	30.00%	30.00%
Non-controlling interest in Gel-Del	$ 1,422,180	$ 1,422,180

Agreement and Plan of Merger -

Agreement and Plan of Merger - Schedule of Recognized Identified Assets Acquired and Liabilities Assumed (Details)	Dec. 31, 2017USD ($)
Agreement And Plan Of Merger - Schedule Of Recognized Identified Assets Acquired And Liabilities Assumed Details
Current assets	$ 13,918
Property and equipment	107,300
Intangible assets (patents & trademarks)	2,180,000
Non-controlling interest in Gel-Del	1,422,180
Total assets acquired	3,723,398
Total liabilities assumed	1,543,398
Net assets acquired	$ 2,180,000

Lease and Commitments (Details

Lease and Commitments (Details Narrative)	9 Months Ended
	Dec. 31, 2017USD ($)ft²
Commitments and Contingencies Disclosure [Abstract]
Area of land | ft²	3,577
Rent expense | $	$ 2,078

Lease and Commitments - Schedul

Lease and Commitments - Schedule of Future Minimum Rental Commitments (Details)	Dec. 31, 2017USD ($)
Commitments and Contingencies Disclosure [Abstract]
2,018	$ 24,932
2,019	24,932
2,020	24,932
2,021	24,932
2,022	24,932
2,023	24,932
2,024	21,774
Future minimum rental commitments	$ 171,366

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($)	Feb. 28, 2018	Dec. 31, 2017	Dec. 31, 2016	Dec. 28, 2017	Dec. 18, 2017	Jul. 28, 2017	Sep. 19, 2016	Jun. 07, 2016	Apr. 11, 2016	Aug. 05, 2015
Debt conversion converted instrument, amount		$ 12,500
Purchase warrants price per unit		$ 0.52		$ 1	$ 0.50	$ 0.30	$ 1.50	$ 2	$ 2	$ 3.50
Number of common shares issued for services
Subsequent Event [Member]
Purchase warrants shares	330,673
Purchase warrants price per unit	$ 0.50
Purchase warrant term	3 years
Subsequent Event [Member] | Consulting and Business Management [Member]
Number of common shares issued for services	10,000
Shares issued price per share	$ 1.50
Subsequent Event [Member] | Gel-Del Technologies, Inc [Member]
Debt conversion converted instrument, amount	$ 181,966
Debt conversion converted instrument, shares	425,287
Subsequent Event [Member] | Patent Law Firm [Member]
Purchase warrants shares	20,000
Purchase warrants price per unit	$ 1
Purchase warrant term	3 years